Novel Contrast Agents and Imaging Methods for Early Detection of Diseases

The novel contrast agents and imaging methods for early detection of diseases comprising:

• labelling the compounds { polyphenols such as curcumin, rosmarinic acid, phenylindane, silibinin, silymarin, thearubigins, theaflavin and its derivatives, theaflavin-3-gallate, tannic acid, catechin, epicatechin, gallocatechin, catechin gallate, gallocatechin gallate, epicatechin gallate, epigallocatechin, and epigallocatechin gallate, stilbene derivatives and others, except stilbene derivatives for amyloid beta detection only by SPECT;
• flavonoids such as luteolin, quercetin, rutin, taxifolin, resveratrol, myricetin, rhein, and others;
• congo red and it’s analogs such as chrysamine-g;
• nordihydroguaiaretic acid;
• cannabinoids such as tetrahydrocannabinol (THC), cannabidiol (CBD), cannabigerol (CBG), and other cannabinoids;
• phenolic acids such as caffeic acid, ferulic acid, gallic acid, salicylic acid, and other phenolic acid;
• nonsteroidal anti-inflammatory drugs (NSAIDs) drugs like sodium salicylate, aspirin, diclofenac, celecoxib and other drugs;
• tannins from brown algae such as phlorotannins include eckol, and it’s derivatives and most polyphenols of seaweed and marine algae;
• compounds like bromophenols and their derivatives, iodophenols and their derivatives, bromoquinols and their derivatives, iodoquinols and their derivatives} by radiotracers such as iodine-123, thallium-20, technetium-99m, xenon-133, and fluorine-18 and other radiotracers which emitted gamma rays detected by SPECT to detect amyloid beta, tau protein, alpha-synuclein protein, and aggregation proteins in neurodegenerative diseases and inflammation in many diseases such as neurodegenerative diseases, cancer and other inflammatory diseases, aggressive cancer tissue, brain activation in neurodegenerative diseases and other diseases by binding and accumulation of the these novel contrast agents to these proteins and diseases by way of the SPECT machine;
• the SPECT images contrast (brightness of images) increase as the binding of these agents to the target diseases are increased.

The novel contrast agents and imaging methods for early detection of diseases comprising:

• labelling the compounds { polyphenols such as curcumin, rosmarinic acid, phenylindane, silibinin, silymarin, thearubigins, theaflavin and its derivatives, theaflavin-3-gallate, tannic acid, catechin, epicatechin, gallocatechin, catechin gallate, gallocatechin gallate, epicatechin gallate, epigallocatechin, and epigallocatechin gallate, stilbene derivatives, and others, except stilbene derivatives for amyloid beta detection only by PET;
• flavonoids such as luteolin, quercetin, rutin, taxifolin, resveratrol, myricetin, rhein, and others;
• congo red and it’s analogs such as chrysamine-g;
• nordihydroguaiaretic acid;
• cannabinoids such as tetrahydrocannabinol (THC), cannabidiol (CBD), cannabigerol (CBG), and other cannabinoids;
• phenolic acids such as caffeic acid, ferulic acid, gallic acid, salicylic acid, and other phenolic acid;
• nonsteroidal anti-inflammatory drugs (NSAIDs) drugs like sodium salicylate, aspirin, diclofenac, celecoxib and other drugs;
• tannins from brown algae such as phlorotannins include eckol, and it’s derivatives and most polyphenols of seaweed and marine algae;
• compounds like bromophenols and their derivatives, iodophenols and their derivatives, bromoquinols and their derivatives, iodoquinols and their derivatives} by radiotracers or isotopes such as iodine-124, iodine-131, fluorine-18, carbon-11, nitrogen-13 and other radiotracers or isotopes that used in PET scan and which emitted positrons detected by PET to detect amyloid beta, tau protein, alpha-synuclein protein, and aggregation proteins in neurodegenerative diseases and inflammation in many diseases such as neurodegenerative diseases, cancer and other inflammatory diseases, aggressive cancer tissue, brain activation in neurodegenerative diseases and other diseases by binding and accumulation of the these novel contrast agents to these proteins and diseases by way of the PET machine;
• the PET images contrast (brightness of images) increase as the binding of these agents to the target diseases are increased.